Literature DB >> 16842393

Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.

Ya-Chi Chen1, S Karl Gotzkowsky, Anne N Nafziger, Robert W Kulawy, Mario L Rocci, Joseph S Bertino, Angela D M Kashuba.   

Abstract

AIMS: A non-invasive proposed method for measuring CYP3A activity is the urinary 6beta-hydroxycortisol:cortisol ratio. This ratio has been used as an indicator of CYP3A induction and inhibition, with mixed results. This investigation evaluated the relationship between a validated, biomarker, intravenous midazolam clearance and the urinary cortisol ratio under constitutive conditions and with the influence of a moderate CYP3A inhibitor.
METHODS: This was a sequential, cross-over study design. Intravenous midazolam 0.025 mg kg(-1) was administered to 10 male and 10 female subjects once every 14 days for 4 months. Fluvoxamine 150 mg day(-1) was given to all subjects during the last two visits. Total body clearance of midazolam and urinary 6beta-hydroxycortisol:cortisol molar ratio were used as biomarkers of hepatic CYP3A activity.
RESULTS: No significant correlations were found between these two markers (r(2) < 0.5, P > 0.05). Larger interindividual and intra-individual variability in CYP3A activity was observed in 6beta-hydroxycortisol:cortisol ratios compared with midazolam clearances. With fluvoxamine therapy, midazolam clearance values decreased approximately 1.5-fold and cortisol ratios decreased approximately 1.9-fold.
CONCLUSIONS: The high intra-individual variability of the urinary cortisol ratio, compared with midazolam, makes this a suboptimal CYP3A phenotyping tool.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16842393      PMCID: PMC1885097          DOI: 10.1111/j.1365-2125.2006.02628.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

1.  An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity.

Authors:  Janyce F Rogers; Mario L Rocci; David B Haughey; Joseph S Bertino
Journal:  Clin Pharmacol Ther       Date:  2003-03       Impact factor: 6.875

Review 2.  Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Authors:  D S Streetman; J S Bertino; A N Nafziger
Journal:  Pharmacogenetics       Date:  2000-04

3.  Midazolam and cortisol metabolism before and after CYP3A induction in humans.

Authors:  S L Eeckhoudt; J P Desager; A R Robert; I Leclercq; R K Verbeeck; Y Horsmans
Journal:  Int J Clin Pharmacol Ther       Date:  2001-07       Impact factor: 1.366

4.  A wide interindividual variability of urinary 6beta-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition.

Authors:  Kazuhiro Inagaki; Masami Inagaki; Tomomi Kataoka; Izumi Sekido; Mark A Gill; Mikio Nishida
Journal:  Ther Drug Monit       Date:  2002-12       Impact factor: 3.681

5.  Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease.

Authors:  Thomas C Dowling; Andrew E Briglia; Jeffrey C Fink; Donna S Hanes; Paul D Light; Lucy Stackiewicz; Chetan S Karyekar; Natalie D Eddington; Matthew R Weir; William L Henrich
Journal:  Clin Pharmacol Ther       Date:  2003-05       Impact factor: 6.875

6.  Comparison of urinary 6-beta-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity.

Authors:  P B Watkins; D K Turgeon; P Saenger; K S Lown; J C Kolars; T Hamilton; K Fishman; P S Guzelian; J J Voorhees
Journal:  Clin Pharmacol Ther       Date:  1992-09       Impact factor: 6.875

7.  Evidence for the validity of cortisol 6 beta-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans.

Authors:  Takashi Furuta; Atsushi Suzuki; Chieko Mori; Hiromi Shibasaki; Akitomo Yokokawa; Yasuji Kasuya
Journal:  Drug Metab Dispos       Date:  2003-11       Impact factor: 3.922

8.  Drug interaction potential of soy extract and Panax ginseng.

Authors:  Gail D Anderson; Gina Rosito; Michael A Mohustsy; Gary W Elmer
Journal:  J Clin Pharmacol       Date:  2003-06       Impact factor: 3.126

9.  Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females.

Authors:  Markus Wenk; Liliane Todesco; Stephan Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

10.  Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.

Authors:  Hideki Ushiama; Hirotoshi Echizen; Shinobu Nachi; Akihiro Ohnishi
Journal:  Clin Pharmacol Ther       Date:  2002-07       Impact factor: 6.875

View more
  10 in total

Review 1.  Interindividual Variability in Cytochrome P450-Mediated Drug Metabolism.

Authors:  Timothy S Tracy; Amarjit S Chaudhry; Bhagwat Prasad; Kenneth E Thummel; Erin G Schuetz; Xiao-Bo Zhong; Yun-Chen Tien; Hyunyoung Jeong; Xian Pan; Laura M Shireman; Jessica Tay-Sontheimer; Yvonne S Lin
Journal:  Drug Metab Dispos       Date:  2015-12-17       Impact factor: 3.922

Review 2.  Phenotyping of Human CYP450 Enzymes by Endobiotics: Current Knowledge and Methodological Approaches.

Authors:  Gaëlle Magliocco; Aurélien Thomas; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

3.  Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity: a comment.

Authors:  Martin Fenske
Journal:  Br J Clin Pharmacol       Date:  2006-11-10       Impact factor: 4.335

4.  Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics.

Authors:  F T Aweeka; C Hu; L Huang; B M Best; A Stek; P Lizak; S K Burchett; J S Read; H Watts; M Mirochnick; E V Capparelli
Journal:  HIV Med       Date:  2014-11-18       Impact factor: 3.180

5.  Distribution of Exogenous and Endogenous CYP3A Markers and Related Factors in Healthy Males and Females.

Authors:  Jieon Lee; Andrew HyoungJin Kim; SoJeong Yi; SeungHwan Lee; Seo Hyun Yoon; Kyung-Sang Yu; In-Jin Jang; Joo-Youn Cho
Journal:  AAPS J       Date:  2017-05-18       Impact factor: 4.009

6.  Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.

Authors:  Xi Luo; Xiao-min Li; Zhe-yi Hu; Ze-neng Cheng
Journal:  Acta Pharmacol Sin       Date:  2009-08-24       Impact factor: 6.150

7.  Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women.

Authors:  Rosa F Yeh; Naser L Rezk; Angela D M Kashuba; Julie B Dumond; Hiba L Tappouni; Hsiao-Chuan Tien; Ya-Chi Chen; Manoli Vourvahis; Amanda L Horton; Susan A Fiscus; Kristine B Patterson
Journal:  Antimicrob Agents Chemother       Date:  2009-03-23       Impact factor: 5.191

Review 8.  A Physiology-Based Pharmacokinetic Framework to Support Drug Development and Dose Precision During Therapeutic Hypothermia in Neonates.

Authors:  Anne Smits; Pieter Annaert; Steven Van Cruchten; Karel Allegaert
Journal:  Front Pharmacol       Date:  2020-05-13       Impact factor: 5.810

9.  Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the "Missing Heritability" Problem.

Authors:  Kathrin Klein; Ulrich M Zanger
Journal:  Front Genet       Date:  2013-02-25       Impact factor: 4.599

10.  Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.

Authors:  Catherine Dutreix; Sebastien Lorenzo; Yanfeng Wang
Journal:  Eur J Clin Pharmacol       Date:  2014-05-21       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.